Johnson & Johnson (JNJ) Shares Bought by Bartlett & Co. LLC

Bartlett & Co. LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 225,546 shares of the company’s stock after buying an additional 8,628 shares during the period. Bartlett & Co. LLC’s holdings in Johnson & Johnson were worth $27,368,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wade G W & Inc. lifted its stake in Johnson & Johnson by 3.1% in the first quarter. Wade G W & Inc. now owns 150,262 shares of the company’s stock valued at $19,256,000 after acquiring an additional 4,478 shares during the last quarter. M&T Bank Corp lifted its stake in Johnson & Johnson by 0.3% in the first quarter. M&T Bank Corp now owns 2,435,770 shares of the company’s stock valued at $312,144,000 after acquiring an additional 6,838 shares during the last quarter. Abacus Planning Group Inc. lifted its stake in Johnson & Johnson by 15.5% in the first quarter. Abacus Planning Group Inc. now owns 8,916 shares of the company’s stock valued at $1,143,000 after acquiring an additional 1,195 shares during the last quarter. Eagle Global Advisors LLC lifted its stake in Johnson & Johnson by 1.6% in the first quarter. Eagle Global Advisors LLC now owns 77,460 shares of the company’s stock valued at $9,927,000 after acquiring an additional 1,221 shares during the last quarter. Finally, Aspiriant LLC lifted its stake in Johnson & Johnson by 185.3% in the first quarter. Aspiriant LLC now owns 49,107 shares of the company’s stock valued at $6,293,000 after acquiring an additional 31,892 shares during the last quarter. Institutional investors and hedge funds own 66.60% of the company’s stock.

A number of analysts have commented on the stock. Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 price target on shares of Johnson & Johnson in a research note on Friday, September 14th. Jefferies Financial Group set a $145.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. HC Wainwright reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Credit Suisse Group set a $149.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, October 14th. Finally, ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $142.54.

In other news, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the transaction, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Ronald A. Kapusta sold 8,441 shares of the stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $145.15, for a total transaction of $1,225,211.15. Following the completion of the transaction, the chief accounting officer now directly owns 17,284 shares in the company, valued at $2,508,772.60. The disclosure for this sale can be found here. Insiders sold 85,340 shares of company stock worth $11,992,396 over the last three months. Insiders own 0.22% of the company’s stock.

Shares of JNJ opened at $145.34 on Friday. The stock has a market capitalization of $382.50 billion, a PE ratio of 19.91, a P/E/G ratio of 2.23 and a beta of 0.58. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.32. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The company’s revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.90 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be given a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.48%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s payout ratio is presently 49.32%.

WARNING: “Johnson & Johnson (JNJ) Shares Bought by Bartlett & Co. LLC” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/11/10/johnson-johnson-jnj-shares-bought-by-bartlett-co-llc.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Does the discount rate affect the economy?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply